The test, which uses automated reverse-transcription real-time PCR, expands the firm's menu of CLIA-waived tests for use in near-patient and point-of-care settings.
The portable, battery-operated system will be an interim solution for decentralized testing in places where power may be unreliable.
The company's Life Sciences segment was up 17 percent year over year, while its Diagnostics business grew 8 percent.
The company's Diagnostics business was up 14 percent, while its Life Sciences business grew 13 percent. The firm also closed its $2 billion buy of IDT last week.
Providers are looking to innovation in products and pricing to convince pathologists unsure of the value in switching to digital solutions.
The company will use a portion of the credit facility to fund its announced acquisition of Integrated DNA Technologies.
IDT will operate as a standalone company within Danaher's Life Sciences segment after the close of the deal, which is expected to occur in mid-2018.